BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Top 10 Therapy Groups account for nearly 80% of India's Pharma Market in October 2026

14 November 2026 | News | By Narayan Kulkarni

Cardiac, gastrointestinal and anti-infective therapies lead market contribution, while anti-diabetic and vitamins segments record strong value growth



India's pharmaceutical market continued to be driven by its leading therapy segments in October 2026, with the top 10 therapy groups accounting for approximately 79.9 per cent of the total market value. Cardiac, gastrointestinal and anti-infective medicines emerged as the three largest contributors, together accounting for 37.1 per cent of the Indian Pharmaceutical Market (IPM).

According to data from Pharmarack Technologies, the cardiac segment topped the therapy rankings with sales of Rs 3,338 crore in October 2026, representing 13.8 per cent of the market and registering 13.5 per cent value growth. Gastrointestinal medicines followed with sales of Rs 2,786 crore, contributing 11.5 per cent to the market and recording 14.2 per cent growth.

Anti-infectives ranked third, with sales of Rs 2,811 crore and an 11.6 per cent market share, although value growth remained relatively modest at 6.9 per cent. Anti-diabetic medicines contributed Rs 2,314 crore, accounting for 9.6 per cent of the market, with value growth of 14.7 per cent.

Vitamins, minerals and nutrients recorded sales of Rs 2,233 crore, contributing 9.2 per cent to the market and registering 17 per cent growth, the highest among the top five therapy groups. Respiratory medicines accounted for 7.7 per cent of the market, with sales of Rs 1,865 crore, but registered comparatively lower growth of 3.8 per cent.

Pain and analgesics contributed Rs 1,728 crore, representing 7.1 per cent of the market, and recorded 14.9 per cent growth. Neuro and central nervous system (CNS) therapies generated Rs 1,604 crore, with a 6.6 per cent market share and 10.9 per cent growth. Dermatology recorded sales of Rs 1,547 crore, contributing 6.4 per cent to the market and growing 12.7 per cent.

The top 10 were rounded off by gynaecological therapies, which recorded sales of Rs 732 crore, a 3 per cent market share and 15.9 per cent value growth.

Across these leading therapy groups, vitamins, minerals and nutrients, gynaecological medicines and pain/analgesics recorded particularly strong growth, while respiratory medicines and anti-infectives experienced relatively slower expansion.

Overall, the IPM recorded sales of Rs 24,212 crore in October 2026, registering value growth of 12.23 per cent and unit growth of 1.58 per cent.

Top 10 therapy groups – October 2026

Rank	Therapy group	Sales (Rs Cr)	Market share	Value growth
1	Cardiac	3,338	13.8%	13.5%
2	Anti-infectives	2,811	11.6%	6.9%
3	Gastrointestinal	2,786	11.5%	14.2%
4	Anti-diabetic	2,314	9.6%	14.7%
5	Vitamins/minerals/nutrients	2,233	9.2%	17.0%
6	Respiratory	1,865	7.7%	3.8%
7	Pain/analgesics	1,728	7.1%	14.9%
8	Neuro/CNS	1,604	6.6%	10.9%

9	Derma	1,547	6.4%	12.7%
10	Gynaecological	732	3.0%	15.9%

Narayan Kulkarni

(narayan.kulkarni@mmactiv.com)